Neuland Labs

Indian CDMO with dedicated peptide manufacturing facility opening summer 2026. SPPS, LPPS, and hybrid peptide synthesis. USFDA/EMA/PMDA inspected. 6,370L reactor capacity in first module. Over 40 years of complex API development experience.

Directory assessment: Neuland Labs is listed as a CDMO in the peptide supply chain, serving Asia markets from India (Hyderabad). As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. Verification is based on publicly available information and cross-referenced against industry databases. This supplier has a strong confidence score, indicating a high level of verification and reliability for B2B sourcing.